ArticleJournal of nanobiotechnology2023
NIR/pH-triggered aptamer-functionalized DNA origami nanovehicle for imaging-guided chemo-phototherapy.
Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 40 citations in OpenAlex.
- 4D nanoimaging-guided smart therapeutics: spatiotemporal control of disease microenvironments.RSC advances · 2026Review
- Dynamic DNA Nanomachines for Biosensing and Drug Delivery.Sensors (Basel, Switzerland) · 2026Review
- Framework Nucleic Acids as a Nanocontainer for Delivering Heterogeneous Molecular Drugs.Pharmaceutics · 2026Review
- Recent Advances in Novel Drug Delivery Systems for the Management of Cutaneous Squamous Cell Carcinoma.International journal of nanomedicine · 2026Review
- Synthesis of near-infrared molybdenum oxide nanoparticle-functionalized metal-organic frameworks and their application in antitumor studies.Mikrochimica acta · 2025Article
- Aptamer-based NIR II imaging for breast cancer surgical resection.Npj imaging · 2025Article
- Controllable nickel ions release from deferoxamine mesylate-triggered nickel-iron layered double hydroxide for eliciting apoptotic cell death in prostate cancer.Journal of nanobiotechnology · 2025Article
- Phototherapy in cancer treatment: strategies and challenges.Signal transduction and targeted therapy · 2025Review
- A Multifunctional MIL-101-NHInternational journal of nanomedicine · 2025Article
- Review
- Doxorubicin-loaded DNA origami nanostructures: stability in vitreous and their uptake and toxicity in ocular cells.Nanoscale · 2024Article
- Advancements in Aptamer-Driven DNA Nanostructures for Precision Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- DNA-Based Nanostructured Platforms as Drug Delivery Systems.Chem & bio engineering · 2024Review
- A TSHR-Targeting Aptamer in Monocytes Correlating with Clinical Activity in TAO.International journal of nanomedicine · 2024Article
- SiRNF8 Delivered by DNA Framework Nucleic Acid Effectively Sensitizes Chemotherapy in Colon Cancer.International journal of nanomedicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Targeted chemo-phototherapy has received widespread attention in cancer treatment for its advantages in reducing the side effects of chemotherapeutics and improving therapeutic effects. However, safe and efficient targeted-delivery of therapeutic agents remains a major obstacle. Herein, we successfully constructed an AS1411-functionalized triangle DNA origami (TOA) to codeliver chemotherapeutic drug (doxorubicin, DOX) and a photosensitizer (indocyanine green, ICG), denoted as TOADI (DOX/ICG-loaded TOA), for targeted synergistic chemo-phototherapy. In vitro studies show that AS1411 as an aptamer of nucleolin efficiently enhances the nanocarrier's endocytosis more than 3 times by tumor cells highly expressing nucleolin. Subsequently, TOADI controllably releases the DOX into the nucleus through the photothermal effect of ICG triggered by near-infrared (NIR) laser irradiation, and the acidic environment of lysosomes/endosomes facilitates the release. The downregulated Bcl-2 and upregulated Bax, Cyt c, and cleaved caspase-3 indicate that the synergistic chemo-phototherapeutic effect of TOADI induces the apoptosis of 4T1 cells, causing ~ 80% cell death. In 4T1 tumor-bearing mice, TOADI exhibits 2.5-fold targeted accumulation in tumor region than TODI without AS1411, and 4-fold higher than free ICG, demonstrating its excellent tumor targeting ability in vivo. With the synergetic treatment of DOX and ICG, TOADI shows a significant therapeutic effect of ~ 90% inhibition of tumor growth with negligible systemic toxicity. In addition, TOADI presents outstanding superiority in fluorescence and photothermal imaging. Taken together, this multifunctional DNA origami-based nanosystem with the advantages of specific tumor targeting and controllable drug release provides a new strategy for enhanced cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.